TumorBoardTuesday4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea
6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell
✳️Dual ICI combo (ipi + nivo) also approved tx option
💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts
✳️Dual ICI combo (ipi + nivo) also approved tx option
💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
